Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial

Lupus

Volumn 25, Issue 3, 2016, Pages 301-306

  Pengo, Vittorio ^a   Banzato, A ^a   Bison, E ^a   Zoppellaro, G ^a   Padayattil Jose, S ^a   Denas, G ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

antiphospholipid; APS; rivaroxaban; syndrome; trial; warfarin

Indexed keywords

RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; ADOLESCENT; AGED; BLEEDING; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FEMALE; INTERNATIONAL NORMALIZED RATIO; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; CLINICAL PROTOCOLS; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; RIVAROXABAN; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN; YOUNG ADULT;

EID: 84959175335     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315611495     Document Type: Article

References (24)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Pierangeli SS, de Groot PG, Dlott J, et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011; 20: 182-190.
3. Lee EY, Lee CK, Lee TH, et al. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res 2003; 111: 29-32.
4. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S,. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152.
5. Sailer T, Zoghlami C, Kurz C, et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 2006; 95: 796-801.
6. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160-1165.
7. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V,. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123: 482-287.
8. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: Antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; 13: 782-787.
9. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-242.
10. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New Engl J Med 2003; 349: 1133-1138.
11. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.
12. Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med 2010; 363: 2499-2510.
13. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891.
14. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. New Engl J Med 2012; 366: 9-19.
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG,. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Informatics 2009; 42: 377-381.
16. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34: 2094-2106.
17. Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med 2012; 366: 1287-1297.
18. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322.
19. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-218.
20. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR,. The management of thrombosis in the antiphospholipid-antibody syndrome. New Engl J Med 1995; 332: 993-997.
21. Pengo V, Biasiolo A, Pegoraro C,. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. Am J Cardiol 2001; 88: 1214-1216.
22. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119: 2920-2927.
23. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584.
24. Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013; 11: 1527-1531.